Levetiracetam
Product Images NDC 71093-124

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 71093-124). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aci Healthcare Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

1000-mg (1000 mg)

1000-mg (1000 mg)
FDA Label Image

250-mg (250 mg)

250-mg (250 mg)
FDA Label Image

500-mg (500 mg)

500-mg (500 mg)
Each tablet in this medication contains 500 mg of Levetiracetam USP. The dosage recommendations can be found in the package insert. The medication is in tablet form and comes in a bottle containing 120 tablets. It is important to keep this and all medications out of reach of children. The manufacturer of this medication is O VARNISH ZONE.*
FDA Label Image

750-mg (750 mg)

750-mg (750 mg)
FDA Label Image

Fig-1 (Fig 1)

Fig-1 (Fig 1)
This text provides information on the percentage of patients in different treatment groups and their corresponding dosages. The treatment groups include a placebo group (N=95), a levetiracetam 1000 mg/day group (N=97), and a levetiracetam 3000 mg/day group (N=101). However, without further context or additional information, it is not possible to determine the specific purpose or findings of this data.*
FDA Label Image

Fig-2 (Fig 2)

Fig-2 (Fig 2)
This is a comparison of the percentage of patients in three different groups: placebo, levetiracetam 1000 mg/day, and levetiracetam 2000 mg/day. The number of patients in each group is provided in parentheses.*
FDA Label Image

Fig-3 (Fig 3)

Fig-3 (Fig 3)
FDA Label Image

Fig-4 (Fig 4)

Fig-4 (Fig 4)
This text provides the percentage of patients in a study who were given a placebo (n=97) and the percentage of patients who were given levetiracetam (n=101).*
FDA Label Image

Fig-5 (Fig 5)

Fig-5 (Fig 5)
This is a comparison of the percentage of patients who received a placebo (19.6%) versus levetiracetam (43.1%). The study included a total of 51 patients in the placebo group and 58 patients in the levetiracetam group.*
FDA Label Image

Fig-6 (Fig 6)

Fig-6 (Fig 6)
This text provides data on the percentage of patients in a study who were given a placebo (N=84) and levetiracetam (N=79). The percentages of patients for each group are 45.2% for placebo and 72.2% for levetiracetam.*
FDA Label Image

Levestructure (Levestructure)

Levestructure (Levestructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.